Good Morning Investors!!! After a strong week that pushed stocks to fresh highs, futures were lower early Monday as traders digested two big curveballs: new headlines tied to the Federal Reserve (Fed) (U.S. central bank) and fresh talk of a one-year 10% cap on credit card interest rates, which had bank stocks looking a bit queasy. Next up, the Consumer Price Index (key inflation report) hits tomorrow morning, right around the same time that big banks start reporting earnings. We will also zoom in on Communication Services (think ads, streaming, and your endless scrolling) and spotlight Moderna’s latest update from the big healthcare conference.
Key Market DriversFed independence jitters: Markets woke up to Federal Reserve drama after Chair Jerome Powell said the Justice Department / the Trump administration threatened him with a criminal indictment over a renovation. S&P 500 Index futures were down about 0.5% this morning. When investors worry the Fed could get pushed around, they often ask for a higher risk premium (extra pay for extra worry) to hold stocks and the dollar. Gold hit a new record above $4,600 an ounce early Monday, a classic storm-shelter trade. 
S&P 500 1 Year Chart – 1-12-2026
Credit card rate cap scare: Financial stocks took a gut punch after President Trump floated a one-year cap on credit card interest rates at 10%, starting Jan. 20. With little detail on how it would work, lenders slid in premarket (before the open) trading, and names like American Express, Visa, and Mastercard dipped too. Credit cards are a profit engine for banks, so a cap makes investors do the math. If lenders cannot price risk, they may cut credit lines, which can slow spending. It also lands as big banks start earnings season, so expect plenty of questions on those calls. CPI and bank earnings ahead: Tuesday brings the Consumer Price Index (CPI – the key inflation report) for December, and it matters because it can nudge rate cut hopes in a hurry. Last year’s long federal shutdown left some holes in the data, so traders are extra alert for any surprise bounce in prices. Earnings season also starts with major banks, which act like the economy’s cash register and can hint at how the consumer is doing. On Friday, the S&P 500 closed at a record 6,966.28, so the bar is high. Think of this week as a pop quiz for markets. Oil pulled two ways: Oil is doing the tug-of-war thing. On one side, unrest in Iran has traders watching for any hit to supply, especially if shipping near the Strait of Hormuz, a key oil lane, gets messy. On the other, talk of Venezuelan exports coming back keeps a lid on prices. Brent crude was near $63 a barrel and West Texas Intermediate (US oil benchmark) near $59 as of early this morning. Oil feeds into gas prices and inflation, so it can shift rate bets fast. Some banks also see a 2026 supply glut, which could cool energy stocks. |
Thoughts from InvestorsGrow:
Tomorrow’s CPI is the main event. Think of it like checking the weather before a road trip. If it reads “hotter than expected,” traders often push yields up, and stocks can get a bit cranky. If it reads “cooler than expected,” yields often drift down and stocks tend to breathe easier.
Also keep one eye on Core Consumer Price Index (inflation without food and energy). It is less jumpy than headline CPI, so many pros trust it more. If core comes in sticky, rate cut hopes can fade fast. If core cools, it can be a small green light for risk-taking.
JPMorgan kicks off the big-bank parade, and banks are like the economy’s heart monitor. Listen for talk on how often people are late on payments, how much borrowing is happening, and what they see in 2026. Delta adds a “real life” read too, because planes do not fill up on vibes alone.
Communication Services
Communication Services is the sector behind your scroll, stream, and phone bill. It earns money two main ways: ads and subs (subscriptions). A simple yardstick is the Communication Services Select Sector SPDR Fund (XLC), an exchange-traded fund (ETF). XLC rose about 23% over the past year.
This space matters because ad budgets move with the economy. Live sports still pulls in big ad checks, with major events like the 2026 Winter Olympics helping keep demand strong. Policy is a wild card, but fresh draft rules in Europe look set to lean more on “best practices” than hard rules for Big Tech.
Meta Platforms (META):
Meta runs Facebook, Instagram, and WhatsApp, and ads pay most of the bills. Its edge is scale, since its apps reach a huge share of the world each day. The risk is trust, because scam ads and tighter rules can scare off brands.
Netflix (NFLX):
Netflix sells streaming and now has both ad-free and ad-supported plans. Its edge is global reach plus a deep show bench that keeps people watching. Next up is fourth quarter (Q4) (Oct–Dec for most firms) results on Tuesday, Jan 20, after the close, with focus on price hikes, ad growth, and churn (people who quit).
Spotify (SPOT):
Spotify is a global audio streamer with paid and ad-based plans. Its edge is habit, with playlists and podcasts that feel tailor-made. It is also pushing into video, which could lift sales per user but adds cost and competition.
InvestorsGrow Takeaway:
If ads stay firm and subs keep growing, this sector can keep climbing higher. If ad spend fades or rules bite, it can cool off fast.
Moderna (MRNA)
Moderna is a biotech firm that makes vaccines. It uses messenger ribonucleic acid (mRNA) (a short genetic note) to teach your cells to make a harmless protein, so your immune system can learn the “wanted poster.” Its COVID shot made it a household name, but its future depends on new shots like flu and combo vaccines.
On Monday, Moderna said it now expects about $1.9 billion in 2025 sales, near the top end of its prior range. It also said it cut its 2025 cost plan by about $200 million and expects to end 2025 with about $8.1 billion in cash. The update came ahead of a big healthcare investor event where companies try to sell the story, not the stock.
This matters because Moderna is still stepping down from its pandemic peak, and investors want proof the slide is slowing. Higher sales plus lower costs can stretch its cash and reduce the need to raise money soon. In plain English, the company is saying, “We can keep the lights on while we build the next act.”
Here is the gut-check datapoint: $1.9 billion in 2025 sales vs $18.4 billion in 2022. That gap shows how hard it is to swap a one-time wave for steady, repeat demand. Next up, watch for its full-year results on Feb. 13, plus any clearer timing on flu and COVID-flu combo approvals and key trial updates due in 2026.
InvestorsGrow Takeaway:
Moderna is in a “prove it” stretch. The bull case is that cost cuts plus a solid pipeline can turn a COVID hit into a wider vaccine shop. (Term: Pipeline is the list of drugs still in testing.) The red flags are delays, weak demand for new shots, and cash burn that stays too hot. If you follow it, keep an eye on cash levels and new product dates, because in biotech, timing is half the game.
